Chemistry:Birelentinib
From HandWiki
Birelentinib is an investigational new drug that is being developed by for the treatment of immune thrombocytopenia (ITP), and chronic lymphocytic leukemia. It is a dual Bruton's tyrosine kinase (BTK) and tyrosine-protein kinase Lyn inhibitor.[1][2]
References
- ↑ "Birelentinib". AdisInsight. Dizal Pharmaceutical. https://adisinsight.springer.com/drugs/800066716.
- ↑ "Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report". Blood 146 (Supplement 1): 3889. 2025-11-03. doi:10.1182/blood-2025-3889. ISSN 0006-4971.
 |  |
